Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co Cancer Chief Reflects on 'Foundational' Keytruda

Executive Summary

Roger Dansey, head of Merck's clinical development in oncology, tells Scrip that the Keynote clinical program for the blockbuster PD-1 inhibitor continues to hit endpoints across diseases and there is much more to come.

You may also be interested in...



Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal

Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC099483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel